Wall Street analyst estimates for Ernexa Therapeutics Inc. (ERNA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-06 | $-3.84 | ||
| 2026-08-06 | $-3.40 | $-3.30 | -3.0% |
| 2026-05-11 | $-6.95 | $-1.95 | -256.4% |
| 2026-03-13 | $-0.25 | ||
| 2025-11-07 | $-0.15 | $-33.00 | +99.5% |
| 2025-08-13 | $-0.61 | $-39.00 | +98.4% |
| 2025-05-07 | $-2.25 | $-48.00 | +95.3% |
| 2025-03-13 | $-48.00 | $-37.50 | -28.0% |
Valuation Ratios
| Price / Book | 1.45 |
| EV / EBITDA | 0.19 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.3M | $21.3M | $23.3M | $19.8M | 0 | 0 | 0 | $68000 | $582000 | 0 |
| Cost of Revenue | $8.1M | $7.1M | $8.4M | $7.8M | $98000 | 0 | 0 | $236000 | $96000 | 0 |
| Gross Profit | $14.2M | $14.2M | $14.9M | $12.0M | -$98000 | 0 | 0 | -$168000 | $486000 | 0 |
| Research & Development | 0 | $139000 | $72000 | $26000 | $4.0M | $12.7M | $10.4M | $5.9M | $4.6M | $4.2M |
| Selling, General & Admin | $16.5M | $15.4M | $14.4M | $13.1M | $3.3M | $14.7M | $16.6M | $14.6M | $13.1M | $5.2M |
| Operating Expenses | $16.5M | $15.6M | $14.5M | $13.2M | $7.2M | $113.7M | $33.2M | $21.0M | $16.2M | $9.3M |
| Operating Income | -$2.3M | -$1.4M | $464000 | -$1.2M | -$7.2M | -$113.7M | -$33.2M | -$21.1M | -$15.7M | -$9.3M |
| EBITDA | $609000 | $915000 | $3.2M | $1.4M | -$26.4M | -$121.9M | -$24.0M | -$19.9M | -$36.1M | -$13.8M |
| Interest Expense | $576000 | $498000 | $389000 | $249000 | $43000 | $74000 | $30000 | $614000 | $6.8M | $27000 |
| Pre-tax Income | -$2.9M | -$1.0M | -$323000 | -$2.0M | -$26.5M | -$122.5M | -$24.5M | -$21.7M | -$44.5M | -$14.1M |
| Income Tax | $38000 | $66000 | -$64000 | $27000 | 0 | $64000 | $45000 | -$3000 | $30000 | -$45000 |
| Net Income | -$2.9M | -$1.1M | -$259000 | -$2.0M | $11.9M | -$122.5M | -$24.6M | -$21.7M | -$44.5M | -$14.1M |
| EPS | $-1536.00 | $-441.00 | $-96.25 | $-712.00 | $-87.75 | $-1415.25 | $-201.50 | $-102.00 | $-39.25 | $-56.00 |
| EPS (Diluted) | $-1536.00 | $-441.00 | $-96.25 | $-712.00 | $-87.75 | $-1415.25 | $-201.50 | $-102.00 | $-39.25 | $-56.00 |
| Shares Outstanding (Diluted) | $1903 | $2442 | $2688 | $2875 | $69314 | $86600 | $122040 | $212560 | $1.1M | $252280 |
Price
| Price | $3.91 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADAP · AEMD · AEON · DWTX · LNAI · MBRX · MPLT
Explore sector: Healthcare · Biotechnology
More sections of ERNA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks